Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluating the ability of zoledronic acid to reduce the rate of subsequent osteoporotic fractures after a hip fracture

Next Previous
X
Search
Trial Profile

Evaluating the ability of zoledronic acid to reduce the rate of subsequent osteoporotic fractures after a hip fracture

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Bone resorption; Fracture; Osteoporosis
  • Focus Therapeutic Use
  • Acronyms HORIZON-RFT
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 01 Jun 2021 Results of post hoc analysis assessing to determine if zoledronic acid prevents new clinical fractures published in the Osteoporosis International
    • 01 May 2012 Actual end date changed from Nov 2006 to Feb 2007 as reported by ClinicalTrials.gov.
    • 01 Sep 2011 Results published in Osteoporosis International.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top